Alzheimer disease (AD) is characterized by progressive cognitive decline in older individuals accompanied by the presence of two pathological protein aggregates — amyloid-β and phosphorylated tau — in the brain. The disease results in brain atrophy caused by neuronal loss and synapse degeneration. ...
Alzheimer disease (AD) is characterized by progressive cognitive decline in older individuals accompanied by the presence of two pathological protein aggregates — amyloid-β and phosphorylated tau — in the brain. The disease results in brain atrophy caused by neuronal loss and synapse degeneration. ...
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized in the early stages by loss of learning and memory. However, the mechanism underlying these symptoms remains unclear. The best correlation between cognitive decline and pathological changes is in synaptic dysfunction. Histopath...
Alzheimer’s diseasesynaptic dysfunctionamyloid betatau proteinneurograninbiomarkercerebrospinal fluidpathophysiologyearly diagnosisprecision medicineIntroduction: Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of Alzheimer’s disease (AD). In addition, synaptic depletion ...
A series of 150 patients suffering from Alzheimer's disease were studied clinically and morphologically and the brains of 10 cases were also examined by electron microscopy. The following conclusions were drawn: The primary lesion in the brain cortex is seen on the synaptic manifests nerve cell ...
(PREVENT-AD) were used to explore the relationship between PTPRS and various Alzheimer’s disease biomarkers. We identified that PTPRS rs10415488 variant C shows features of neuroprotection against early Tau pathology and synaptic degeneration in Alzheimer’s disease. This single nucleotide polymorphism ...
Li et al. Acta Neuropathologica Communications https://doi.org/10.1186/s40478-018-0626-x (2018) 6:121 RESEARCH Open Access Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease Shaomin Li* , Ming Jin, Lei Liu,...
(ApoE) allotype, and synaptophysin concentration in entorhinal cortex and superior frontal gyrus of normal elderly control (ND) patients, Alzheimer's disease (AD. patients, and high pathology control (HPC) patients who meet pathological criteria for AD but show no synapse loss or overt antemortem...
Alzheimer's disease (AD) is characterised by an increased number of senile plaques (SP) and neurofibrillary tangles (NFT) as compared with that found in non-demented individuals of the same age, and a marked degeneration and loss of synapses. One of the main risk-factors for the disorder is...
Background Tau hyperphosphorylation and accumulation is one of the characteristic hallmarks in Alzheimer disease(AD) brains, which plays a key role in synaptic degeneration in early stage of the disease, with the underlying mechanisms remained largely unclarified. Protein Phosphatase 2 A(PP2A) is the...